Xiyan Lu

Mrs. Xiyan Lu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2019 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
CCChengcong Chen
Chengcong Chen
YHYing Huang
Ying Huang
YZYongmei Zeng
Yongmei Zeng
XLXiyan Lu
Xiyan Lu
GDGuoqing Dong
Guoqing Dong
Background: The most significant manifestation of heart failure is exercise intolerance. This systematic review and meta-analysis was performed to investigate whether dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide 1 receptor agonists (GLP-1 RAs), widely used anti-diabetic drugs, could improve exercise tolerance in heart failure patients with or without type 2 diabetes mellitus. Methods: An electronic search of PubMed, EMBASE and the Cochrane Library was carried out through March 8th, 2019, for eligible trials. Only randomized controlled studies were included. The primary outcome was exercise tolerance [6-min walk test (6MWT) and peak O2 consumption], and the secondary outcomes included quality of life (QoL), adverse events (AEs) and all-cause death. Result: After the literature was screened by two reviewers independently, four trials (659 patients) conducted with heart failure patients with or without type 2 diabetes met the eligibility criteria. The results suggested that targeting the DPP-4-GLP-1 pathway can improve exercise tolerance in heart failure patients [MD 24.88 (95% CI 5.45, 44.31), P = 0.01] without decreasing QoL [SMD -0.51 (95% CI -1.13, 0.10), P = 0.10]; additionally, targeting the DPP-4-GLP-1 pathway did not show signs of increasing the incidence of serious AEs or mortality. Conclusion: Our results suggest that DPP-4 inhibitors or GLP-1 RAs improve exercise tolerance in heart failure patients. Although the use of these drugs for heart failure has not been approved by any organization, they may be a better choice for type 2 diabetes mellitus patients with heart failure. Furthermore, as this pathway contributes to the improvement of exercise tolerance, it may be worth further investigation in exercise-intolerant patients with other diseases.

24 September 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
PLPeipei Liu
Peipei Liu
XLXiyan Lu
Xiyan Lu
MHMiao Huang
Miao Huang
MLMingzhu Li
Mingzhu Li
WWWujin Wang
Wujin Wang
GDGuoqing Dong
Guoqing Dong
Introduction: In boys aged ≥10 years with advanced bone age and impaired growth potential (baseline height SDS < −1.5, BA-CA ≥1.5 years, and PAH < −2 SDS), growth hormone monotherapy, while promoting linear growth, fails to delay skeletal maturation, thus limiting therapeutic efficacy. Although letrozole combined with growth hormone may theoretically “decouple” height gain from epiphyseal closure, high-quality evidence specific to the advanced bone age population remains insufficient, and concerns regarding baseline bias and lack of long-term safety data persist. This study, based on real-world data, aims to clarify the benefits and risks of this combination regimen in promoting linear growth, delaying bone age progression, and improving adult height outcomes. Methods: A retrospective analysis was conducted on clinical data from 64 boys aged ≥10 years with advanced bone age and impaired growth potential treated in our hospital from June 2020 to December 2025 (baseline height SDS < −1.5, BA-CA ≥1.5 years, and PAH < −2 SDS). Patients were divided into a combination therapy group (letrozole + rhGH, n = 36) and a monotherapy group (rhGH alone, n = 28) according to treatment regimen. Changes in height, bone age, annual growth velocity, the ratio of bone age advancement to chronological age progression (ΔBA/ΔCA), and sex hormone levels were compared between the two groups before and after treatment. Results: The mean annual growth velocity in the combination group was (7.7 ± 1.2) cm/year, significantly higher than that in the monotherapy group [(6.7 ± 1.4) cm/year, P < 0.05]. The ΔBA/ΔCA ratio in the combination group was 0.85, significantly lower than that in the monotherapy group (1.12, P < 0.001), indicating better control of bone age progression. Among the 33 patients who had completed treatment, the mean final height was (171.2 ± 3.5) cm in the combination group, compared to (169.8 ± 4.1) cm in the monotherapy group (the difference was not statistically significant, P = 0.291). Discussion: In boys aged ≥10 years with advanced bone age and impaired growth potential, letrozole combined with rhGH significantly improved annual growth velocity and delayed bone age progression compared with rhGH monotherapy. However, the difference in final adult height among those who completed treatment was not statistically significant (1.4 cm, P = 0.291). The significantly better control of bone age advancement (ΔBA/ΔCA) and higher target-height attainment rate suggest a potential benefit of adding letrozole, but larger studies with more participants reaching final height are needed to confirm a meaningful effect on adult height.

30 September 2025 in Endokrynologia Polska
Verified
Journal Article
Open access
PDF file
MHMiao Huang
Miao Huang
GDGuoqing Dong
Guoqing Dong
YZYongmei Zeng
Yongmei Zeng
FWFan Wu
Fan Wu
PLPeipei Liu
Peipei Liu
XLXiyan Lu
Xiyan Lu
Not required for Clinical Vignette. Keywords: Dent disease growth hormone therapy CLCN5 mutation chronic kidney disease growth retardation

7 October 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MHMiao Huang
Miao Huang
XLXiyan Lu
Xiyan Lu
PLPeipei Liu
Peipei Liu
GDGuoqing Dong
Guoqing Dong
MLMingzhu Li
Mingzhu Li
JLJianxu Li
Jianxu Li
Objective: The diagnosis of central precocious puberty (CPP) in girls relies on the invasive gonadotropin-releasing hormone (GnRH) stimulation test. Urinary luteinizing hormone (LH) is a noninvasive candidate biomarker, but evidence from Chinese populations and its integration into multivariable prediction frameworks remain limited. We evaluated the diagnostic accuracy of first-morning urinary LH for CPP, established sex- and pubertal stage–specific reference intervals, and developed a two-step prediction model based on a bone age decomposition. Methods: In this single-center retrospective diagnostic accuracy study, we enrolled 808 children: 295 girls with early breast development (146 CPP, 149 non-CPP), 271 healthy girls, and 242 healthy boys (reference intervals only). First-morning urine was assayed for LH, follicle-stimulating hormone (FSH), and creatinine. Diagnostic performance was evaluated primarily in the 295 symptomatic girls, with an extended analysis in 566 girls including healthy controls; multivariable logistic regression decomposed bone age into chronological age (CA) and the BA–CA difference as separate predictors. Results: Urinary LH showed moderate accuracy for CPP in the primary symptomatic cohort (AUC 0.692, 95% CI 0.630–0.752), peaking in girls aged 7–8 years (AUC 0.708, 95% CI 0.621–0.785); the extended cohort gave similar results (AUC 0.712; secondary, spectrum-extended estimate). The LH-to-creatinine ratio offered no improvement. Basal serum LH was the superior single marker (AUC 0.868 vs 0.692, P < 0.001). The noninvasive Model 1 (CA + BA–CA + urinary LH + breast Tanner stage + uterine length) achieved a C-statistic of 0.853 (sensitivity 73.3%, specificity 83.2%), with CA, BA–CA, and urinary LH as independent predictors. Adding basal serum LH and FSH (Model 2) improved the C-statistic to 0.909; urinary LH retained independent significance (aOR 1.280, P = 0.024), whereas basal FSH was inversely associated with CPP. Bootstrap-corrected C-statistics were 0.838 (Model 1) and 0.893 (Model 2). Pubertal-onset cutoffs were >1.02 mIU/mL in girls and >0.95 mIU/mL in boys. Conclusions: Decomposing bone age into CA and BA–CA enables tiered CPP risk stratification: the noninvasive model supports initial screening without blood sampling, and the complete model refines risk once serum gonadotropins become available. Urinary LH is a clinically useful component of tiered diagnostic algorithms for CPP.